PK-tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children’s Hospital

被引:0
作者
Li Peijing [1 ]
Chen Zhenping [1 ]
Cheng Xiaoling [2 ]
Wang Yan [3 ]
Zhang Ningning [4 ]
Zhen Yingzi [1 ]
Wu Xinyi [5 ]
Wu Runhui
机构
[1] Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
[2] Department of Pharmacy, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
[3] Physiatry Department, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
[4] Department of Radiology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
[5] Nursing Department, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
关键词
Severe hemophilia; Pharmacokinetics; Tertiary prophylaxis;
D O I
暂无
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Importance: Tertiary prophylaxis using a low-dose regimen is usually insufficient to prevent recurrent joint bleeding and deterioration in joint diseases in children with severe hemophilia A. Pharmacokinetic (PK) dosing is a useful approach to increase the precision and efficiency of prophylaxis.Objective: To explore the efficacy of PK-tailored tertiary prophylaxis in children with severe hemophilia A.Methods: We implemented a PK-tailored tertiary prophylaxis program for 15 boys with severe hemophilia A aged 5–16 years at Beijing Children’s Hospital. Following PK testing and a 6-month evaluation period (phase I), 15 patients were divided in two groups according to individual PK data and actual bleeding: (1) a PK-tailored group [modified prophylaxis regimen according to PK data for the next 6 months (phase II);n = 8] and (2) a maintenance group (continued the original regimen for the next 6 months;n = 7). We compared the bleeding rate, infusion frequency, and factor VIII (FVIII) consumption between the two groups.Results: In the PK-tailored group, the median annual joint bleeding rate was reduced from 7.8 in phase I to 1.4 in phase II, mean annual total factor consumption increased from 1619.0 IU/kg in phase I to 2401.9 IU/kg in phase II, and median infusion frequency for prophylaxis increased from 104 times/year in phase I to 156 times/year in phase II (P < 0.05). Although the FVIII consumption increased, it remained at approximately half of the standard method.Interpretation: PK-tailored prophylaxis may represent a more efficient approach to individual prophylaxis in China, but further studies are required to verify this.
引用
收藏
页码:45 / 46-47-48-49
相关论文
共 10 条
[1]  
Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A.[J]..BMC Blood Disorders.2016,
[2]  
Haemophilia in Sweden VII. Incidence; Treatment and Prophylaxis of Arthropathy and other Musculo-Skeletal Manifestations of Haemophilia A and B.[J].Åke Ahlberg.Acta Orthopaedica Scandinavica.2014, sup77
[3]   The principles of PK-tailored prophylaxis [J].
Reininger, A. J. ;
Chehadeh, H. E. .
HAMOSTASEOLOGIE, 2013, 33 (4A) :S32-S35
[4]   Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review [J].
Schrijvers, L. H. ;
Uitslager, N. ;
Schuurmans, M. J. ;
Fischer, K. .
HAEMOPHILIA, 2013, 19 (03) :355-361
[5]   Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy [J].
Lindvall, K. ;
Astermark, J. ;
Bjorkman, S. ;
Ljung, R. ;
Carlsson, K. S. ;
Persson, S. ;
Berntorp, E. .
HAEMOPHILIA, 2012, 18 (06) :855-859
[6]   A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management [J].
Valentino, L. A. ;
Mamonov, V. ;
Hellmann, A. ;
Quon, D. V. ;
Chybicka, A. ;
Schroth, P. ;
Patrone, L. ;
Wong, W. -Y. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (03) :359-367
[7]   Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens [J].
Collins, P. W. ;
Bjorkman, S. ;
Fischer, K. ;
Blanchette, V. ;
Oh, M. ;
Schroth, P. ;
Fritsch, S. ;
Casey, K. ;
Spotts, G. ;
Ewenstein, B. M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (02) :269-275
[8]   Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A [J].
Collins, P. W. ;
Blanchette, V. S. ;
Fischer, K. ;
Bjorkman, S. ;
Oh, M. ;
Fritsch, S. ;
Schroth, P. ;
Spotts, G. ;
Astermark, J. ;
Ewenstein, B. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (03) :413-420
[9]   Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia [J].
Manco-Johnson, Marilyn J. ;
Abshire, Thomas C. ;
Shapiro, Amy D. ;
Riske, Brenda ;
Hacker, Michele R. ;
Kilcoyne, Ray ;
Ingram, J. David ;
Manco-Johnson, Michael L. ;
Funk, Sharon ;
Jacobson, Linda ;
Valentino, Leonard A. ;
Hoots, W. Keith ;
Buchanan, George R. ;
DiMichele, Donna ;
Recht, Michael ;
Brown, Deborah ;
Leissinger, Cindy ;
Bleak, Shirley ;
Cohen, Alan ;
Mathew, Prasad ;
Matsunaga, Alison ;
Medeiros, Desiree ;
Nugent, Diane ;
Thomas, Gregory A. ;
Thompson, Alexis A. ;
McRedmond, Kevin ;
Soucie, J. Michael ;
Austin, Harlan ;
Evatt, Bruce L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (06) :535-544
[10]   Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A [J].
Carlsson, M ;
Berntorp, E ;
Bjorkman, S ;
Lethagen, S ;
Ljung, R .
HAEMOPHILIA, 1997, 3 (02) :96-101